Literature DB >> 12213430

Red blood cell fatty acid profile of chronic renal failure patients receiving maintenance haemodialysis treatment.

A M Koorts1, M Viljoen, M C Kruger.   

Abstract

The fatty acid profile of chronic renal failure (CRF) patients on maintenance haemodialysis treatment (MHT) is abnormal and results point towards an essential fatty acid (EFA) deficiency. However, controversies still exist as to which of the essential fatty acids (EFAs) or EFA-products are decreased. In this study, the results of a comprehensive analysis of the fatty acids, performed on the red blood cells of 14 CRF patients on MHT, are presented. The red blood cell membrane fatty acids determined in this study include a range of saturated fatty acids (SFAs), mono-unsaturated fatty acids (MUFAs) and poly-unsaturated fatty acids (PUFAs). Results confirmed the suggested presence of an essential fatty acid deficiency in CRF patients on MHT. It showed the total content of the n-6 fatty acids (31.66 +/- 3.21 vs 34.67 +/- 2.05), as well as the total content of the PUFAs (37.22 +/- 4.08 vs 40.93 +/- 2.35), to be significantly decreased. The total MUFA content was, in contrast, significantly increased (16.87 +/- 0.91 vs 15.49 +/- 1.18). The EFA deficiency profile seen in this study points towards that of a chronic inflammatory condition. This is borne out by the fact that all three precursors of the eicosanoids--the mediators of various inflammatory and immune responses--were reduced in the presence of an increase in MUFAs as well as SFAs. The possibility of the fatty acid profile of CRF patients on MHT being that of a chronic inflammatory condition is supported by the fact that continuous complement-dependent and complement-independent immune activation, due to bio-incompatibility between blood cells and the dialysis membranes, is known to occur during the dialysis process. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213430     DOI: 10.1054/plef.2002.0375

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  6 in total

1.  Plasma and erythrocyte membrane phospholipids and fatty acids in Italian general population and hemodialysis patients.

Authors:  Mariarita Dessì; Annalisa Noce; Pierfrancesco Bertucci; Gianluca Noce; Stefano Rizza; Alessandro De Stefano; Simone Manca di Villahermosa; Sergio Bernardini; Antonino De Lorenzo; Nicola Di Daniele
Journal:  Lipids Health Dis       Date:  2014-03-21       Impact factor: 3.876

Review 2.  Uremic Sarcopenia and Its Possible Nutritional Approach.

Authors:  Annalisa Noce; Giulia Marrone; Eleonora Ottaviani; Cristina Guerriero; Francesca Di Daniele; Anna Pietroboni Zaitseva; Nicola Di Daniele
Journal:  Nutrients       Date:  2021-01-04       Impact factor: 5.717

3.  Variations in the lipid profile of patients with chronic renal failure treated with pyridoxine.

Authors:  Nelva T de Gómez Dumm; Ana M Giammona; Luis A Touceda
Journal:  Lipids Health Dis       Date:  2003-09-18       Impact factor: 3.876

4.  Does the extracorporeal circulation worsen anemia in hemodialysis patients? Investigation with advanced microscopes of red blood cells drawn at the beginning and end of dialysis.

Authors:  Dimosthenis Stamopoulos; Nerantzoula Bakirtzi; Efthymios Manios; Eirini Grapsa
Journal:  Int J Nanomedicine       Date:  2013-10-11

Review 5.  Effects of fish oil on serum lipid profile in dialysis patients: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Wei Zhu; Chongya Dong; Han Du; He Zhang; Jie Chen; Xiaohong Hu; Feng Hu
Journal:  Lipids Health Dis       Date:  2014-08-08       Impact factor: 3.876

6.  Blood Fatty Acid Status and Clinical Outcomes in Dialysis Patients: A Systematic Review.

Authors:  Ban-Hock Khor; Sreelakshmi Sankara Narayanan; Karuthan Chinna; Abdul Halim Abdul Gafor; Zulfitri Azuan Mat Daud; Pramod Khosla; Kalyana Sundram; Tilakavati Karupaiah
Journal:  Nutrients       Date:  2018-09-21       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.